Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903389 | 0.88 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL10031609 | 0.88 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL204974 | 0.86 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL2259135 | 0.86 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL6948605 | 0.86 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL3601048 | 0.86 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL2707102 | 0.86 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL6941435 | 0.86 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL8389716 | 0.86 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL4499549 | 0.85 | HSD17B10 (0.58) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111822-A1 | 1,2,3-TRIAZOLE PYRROLIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111822-A1 | 1,2,3-TRIAZOLE PYRROLIDINE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | HSD17B10 3796/4885SMN1; SMN2 2159/4885NPC1 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.